Twice-yearly inclisiran injections halve LDL-cholesterol levels
- PMID: 32235900
- DOI: 10.1038/s41569-020-0373-0
Twice-yearly inclisiran injections halve LDL-cholesterol levels
Comment on
-
Advances in lipid-lowering therapy through gene-silencing technologies.Nat Rev Cardiol. 2018 May;15(5):261-272. doi: 10.1038/nrcardio.2018.3. Epub 2018 Feb 8. Nat Rev Cardiol. 2018. PMID: 29417937 Review.
-
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187462 Clinical Trial.
References
Original articles
-
- Ray, K. K. et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1912387 (2020) - DOI - PubMed
-
- Raal, F. J. et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1913805 (2020) - DOI - PubMed
Related article
-
- Nordestgaard, B. G. et al. Advances in lipid-lowering therapy through gene-silencing technologies. Nat. Rev. Cardiol. 15, 261–272 (2018) - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical